Business
Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
Arthrosi Therapeutics, Inc., (Arthrosi) has entered into a definitive agreement to be acquired by Sobi® (STO:SOBI). The acquisition strengthens Sobi's gout franchise by adding pozdeutinurad (AR882), an investigational next-generation, once-daily oral URAT1 inhibitor currently being evaluated in two fully recruited global Phase 3 clinical studies for the potential management of progressive and tophaceous gout and expected to read out in 2026. Pozdeutinurad complements Sobi's pipeline by adding a
About this update from Swedish Orphan Biovitrum Ab
[{"type":"text","content":"- Expands Sobi's pipeline with a highly differentiated new Phase 3 asset in Gout- Acquisition expected to be highly accretive to Sobi's mid- to long-term growth and margin trajectory","length":196,"tagName":"p"},{"type":"text","content":"SAN DIEGO, Dec. 15, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., (Arthrosi) has entered into a definitive agreement to be acquired by Sobi® (STO:SOBI). The acquisition strengthens Sobi's gout franchise by adding pozdeutinurad (AR882), an investigational next-generation, once-daily oral URAT1 inhibitor currently being evaluated in two fully recruited global Phase 3 clinical studies for the potential management of progressive and tophaceous gout and expected to read out in 2026. Pozdeutinurad complements Sobi's pipeline by adding a potentially best-in-class URAT1 inhibitor for patients sub-optimally treated with first-line therapies. Today's announcement reflects Sobi's commitment to advancing treatment options for people living with gout.","length":768,"tagName":"p"},{"type":"image","alt":"Arthrosi Logo (PRNewsfoto/Arthrosi Therapeutics)","displaySize":"","headline":null,"caption":"Arthrosi Logo (PRNewsfoto/Arthrosi Therapeutics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":90,"url":"https://media.zenfs.com/en/prnewswire.com/607a1f75016baadf1de3e0efdd8d86a4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yuCNkdqZRHCIqC.0y7XV4Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE1OTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/607a1f75016baadf1de3e0efdd8d86a4","width":400,"height":90}},"href":"https://mma.prnewswire.com/media/2247331/Arthrosi_logo_v2_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""The acquisition of Arthrosi allows us to expand our gout pipeline with a highly differentiated new asset", said Guido Oelkers, President and CEO of Sobi. "Pozdeutinurad has the potential to become the therapy of choice for patients who have progressive gout with persistent and unresolved symptoms despite first-line therapy. The product has the potential to materially accelerate our growth until the mid 2030s, and beyond. We welcome all members of the talented Arthrosi team and are looking forward to working closely together to be able to offer this therapy to patients as soon as possible.&qu...